Stemmatters, a biotechnology company based in Guimarães and located at Avepark – Science and Technology Park, is attending the 32nd Congress of the European Society of Gene & Cell Therapy (ESGCT), taking place in Seville until October 10. This is one of the most relevant international events in the field of cell and gene therapies, bringing together leading researchers, companies, and professionals in the sector.
The presence in Seville reflects the international recognition of the work developed in Guimarães and highlights the importance of Avepark as a hub for incubation and growth of technology and science-based companies that project the region’s name beyond borders.
Founded and developed in Guimarães, Stemmatters operates as a CDMO (Contract Development and Manufacturing Organization), specializing in regenerative medicine products. The company has solid expertise in the development of advanced therapy medicinal products (ATMPs) based on cells, as well as complex blood-derived biological products.
With its facilities based at Avepark, Stemmatters has established itself as a center of innovation and excellence, combining science, technology, and industry to accelerate the clinical translation of high-impact medicines. Its investment in proprietary platforms, such as mimsys®, strengthens its ability to develop pioneering solutions that can transform the future of healthcare.
